Janine Pöss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janine Pöss has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Michael Böhm
Universitätsklinikum des Saarlandes
3 shared publicationsA. Link
Universitätsklinikum des Saarlandes
2 shared publicationsFelix Mahfoud
Universitätsklinikum des Saarlandes
2 shared publicationsM. Böhm
Universitätsklinikum des Saarlandes
2 shared publicationsUlrich Laufs
Universitätsklinikum des Saarlandes
2 shared publicationsA Link
Angiologie und Internistische Intensivmedizin Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Kardiologie Homburg/Saar Germany
1 shared publication
Latest Publications
- 31 October 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 103 (1) , 41-47
Association of vitamin D status and blood pressure response after renal denervation
Vitamin D deficiency is associated with hypertension; however, it is unclear whether vitamin D influences therapeutic blood pressure reduction. Renal sympathetic denervation (RDN) reduces blood pressure in resistant hypertension. We hypothesized that vitamin D might influence blood pressure response to RDN.
- 31 October 2013
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 103 (1) , 41-47
Association of vitamin D status and blood pressure response after renal denervation
Vitamin D deficiency is associated with hypertension; however, it is unclear whether vitamin D influences therapeutic blood pressure reduction. Renal sympathetic denervation (RDN) reduces blood pressure in resistant hypertension. We hypothesized that vitamin D might influence blood pressure response to RDN.
- 23 October 2013
- Published by Springer Nature in Herz
- Vol. 38 (8) , 812-820
Akute und chronische Herzinsuffizienz im Spiegel der neuen ESC-Leitlinie
- 23 October 2013
- Published by Springer Nature in Herz
- Vol. 38 (8) , 812-820
Akute und chronische Herzinsuffizienz im Spiegel der neuen ESC-Leitlinie
- 1 October 2013
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 94 (4) , 499-508
Pharmacological Treatment of Acute Heart Failure: Current Treatment and New Targets
Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF). It is a life-threatening situation in which diagnosis and initiation of therapy are crucial. The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates. Few treatments have been investigated in clinical trials. This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.
- 1 October 2013
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 94 (4) , 499-508
Pharmacological Treatment of Acute Heart Failure: Current Treatment and New Targets
Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF). It is a life-threatening situation in which diagnosis and initiation of therapy are crucial. The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates. Few treatments have been investigated in clinical trials. This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.
- 12 June 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (25/26) , 1360-1364
Chronische und akute Herzinsuffizienz
Im Juni 2012 wurden von der Europäischen Gesellschaft für Kardiologie (ESC) die neuen europäischen Leitlinien zur akuten und chronischen Herzinsuffizienz mit reduzierter sowie erhaltener Ejektionsfraktion vorgestellt. Die Gabe von Mineralokortikoid-Rezeptor-Antagonisten (MRA) ist nun in allen Stadien der unter Betablockade und ACE-Hemmer-Therapie weiterhin symptomatischen chronischen Herzinsuffizienz indiziert. Dies beruht auf den Ergebnissen der EMPHASIS-HF-Studie. Patienten mit Herzinsuffizienz NYHA II–IV, einer EF < 35 % und einem Sinusrhythmus mit einer Herzfrequenz > 70 /min vor dem Hintergrund einer vollständigen medikamentösen Herzinsuffizienztherapie einschließlich maximal tolerierter Betablockade, sollten mit dem If-Kanal-Hemmer Ivabradin behandelt werden. Diese Empfehlung basiert auf der SHIFT-Studie und einigen Anschlussanalysen. Die RAFT-Studie begründete die erweiterte Indikation für CRT-Systeme bei Patienten im Sinusrhythmus und einer Kammerkomplexbreite von > 130 ms mit Linksschenkelblock-Konfiguration. Im Bereich der akuten Herzinsuffizienz hat die RELAX-AHF-Studie mit dem Derivat des Schwangerschaftshormons Relaxin hoffnungsvolle Ergebnisse gezeigt, die zur Durchführung großer Placebo-kontrollierter Studien mit harten klinischen Endpunkten auffordert. Die nachfolgende Übersicht befasst sich mit den Innovationen dieser Leitlinien und fasst die zugrundeliegenden Studien zusammen, wobei sie sich auf die chronische systolische und die akute Herzinsuffizienz fokussiert.
- 12 June 2013
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 138 (25/26) , 1360-1364
Chronische und akute Herzinsuffizienz
Im Juni 2012 wurden von der Europäischen Gesellschaft für Kardiologie (ESC) die neuen europäischen Leitlinien zur akuten und chronischen Herzinsuffizienz mit reduzierter sowie erhaltener Ejektionsfraktion vorgestellt. Die Gabe von Mineralokortikoid-Rezeptor-Antagonisten (MRA) ist nun in allen Stadien der unter Betablockade und ACE-Hemmer-Therapie weiterhin symptomatischen chronischen Herzinsuffizienz indiziert. Dies beruht auf den Ergebnissen der EMPHASIS-HF-Studie. Patienten mit Herzinsuffizienz NYHA II–IV, einer EF < 35 % und einem Sinusrhythmus mit einer Herzfrequenz > 70 /min vor dem Hintergrund einer vollständigen medikamentösen Herzinsuffizienztherapie einschließlich maximal tolerierter Betablockade, sollten mit dem If-Kanal-Hemmer Ivabradin behandelt werden. Diese Empfehlung basiert auf der SHIFT-Studie und einigen Anschlussanalysen. Die RAFT-Studie begründete die erweiterte Indikation für CRT-Systeme bei Patienten im Sinusrhythmus und einer Kammerkomplexbreite von > 130 ms mit Linksschenkelblock-Konfiguration. Im Bereich der akuten Herzinsuffizienz hat die RELAX-AHF-Studie mit dem Derivat des Schwangerschaftshormons Relaxin hoffnungsvolle Ergebnisse gezeigt, die zur Durchführung großer Placebo-kontrollierter Studien mit harten klinischen Endpunkten auffordert. Die nachfolgende Übersicht befasst sich mit den Innovationen dieser Leitlinien und fasst die zugrundeliegenden Studien zusammen, wobei sie sich auf die chronische systolische und die akute Herzinsuffizienz fokussiert.
- 7 May 2013
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 2 (3) , 211-218
FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 7 May 2013
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 2 (3) , 211-218
FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.
- 13 April 2013
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 13 (3) , 290-300
Diesel Exhaust Particles Impair Endothelial Progenitor Cells, Compromise Endothelial Integrity, Reduce Neoangiogenesis, and Increase Atherogenesis in Mice
The mechanisms of the harmful cardiovascular effects of small particulate matter are incompletely understood. Endothelial progenitor cells (EPCs) predict outcome of patients with vascular disease. The aim of our study was to examine the effects of diesel exhaust particles (DEP) on EPC and on the associated vascular damage in mice. C57Bl/6 mice were exposed to DEP. 2 μg DEP/day was applicated intranasally for 3 weeks. Exposure to DEP reduced DiLDL/lectin positive EPC to 58.4 ± 5.6 % (p < 0.005). Migratory capacity was reduced to 65.8 ± 3.9 % (p < 0.0001). In ApoE−/− mice, DEP application reduced the number of EPC to 75.6 ± 6.4 % (p < 0.005) and EPC migration to 58.5 ± 6.8 % (p < 0.005). Neoangiogenesis was reduced to 39.5 ± 14.6 % (p < 0.005). Atherogenesis was profoundly increased by DEP treatment (157.7 ± 18.1 % vs. controls, p < 0.05). In cultured human EPC, DEP (0.1–100 μg/mL) reduced migratory capacity to 25 ± 2.6 % (p < 0.001). The number of colony-forming units was reduced to 8.8 ± 0.9 % (p < 0.001) and production of reactive oxygen species was elevated by DEP treatment (p < 0.001). Furthermore, DEP treatment increased apoptosis of EPC (to 266 ± 62 % of control, p < 0.05). In a blood–brain barrier model, DEP treatment impaired endothelial cell integrity during oxygen–glucose deprivation (p < 0.001). Diesel exhaust particles impair endothelial progenitor cell number and function in vivo and in vitro. The reduction in EPC was associated with impaired neoangiogenesis and a marked increase in atherosclerotic lesion formation.
- 13 April 2013
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 13 (3) , 290-300
Diesel Exhaust Particles Impair Endothelial Progenitor Cells, Compromise Endothelial Integrity, Reduce Neoangiogenesis, and Increase Atherogenesis in Mice
The mechanisms of the harmful cardiovascular effects of small particulate matter are incompletely understood. Endothelial progenitor cells (EPCs) predict outcome of patients with vascular disease. The aim of our study was to examine the effects of diesel exhaust particles (DEP) on EPC and on the associated vascular damage in mice. C57Bl/6 mice were exposed to DEP. 2 μg DEP/day was applicated intranasally for 3 weeks. Exposure to DEP reduced DiLDL/lectin positive EPC to 58.4 ± 5.6 % (p < 0.005). Migratory capacity was reduced to 65.8 ± 3.9 % (p < 0.0001). In ApoE−/− mice, DEP application reduced the number of EPC to 75.6 ± 6.4 % (p < 0.005) and EPC migration to 58.5 ± 6.8 % (p < 0.005). Neoangiogenesis was reduced to 39.5 ± 14.6 % (p < 0.005). Atherogenesis was profoundly increased by DEP treatment (157.7 ± 18.1 % vs. controls, p < 0.05). In cultured human EPC, DEP (0.1–100 μg/mL) reduced migratory capacity to 25 ± 2.6 % (p < 0.001). The number of colony-forming units was reduced to 8.8 ± 0.9 % (p < 0.001) and production of reactive oxygen species was elevated by DEP treatment (p < 0.001). Furthermore, DEP treatment increased apoptosis of EPC (to 266 ± 62 % of control, p < 0.05). In a blood–brain barrier model, DEP treatment impaired endothelial cell integrity during oxygen–glucose deprivation (p < 0.001). Diesel exhaust particles impair endothelial progenitor cell number and function in vivo and in vitro. The reduction in EPC was associated with impaired neoangiogenesis and a marked increase in atherosclerotic lesion formation.
- Open Access
- 29 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , R97
Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
Introduction: Regional citrate anticoagulation is safe, feasible and increasingly used in critically ill patients on continuous renal replacement therapy (CRRT). However, in patients with hepatic or multi-organ dysfunction, citrate accumulation may lead to an imbalance of calcium homeostasis. The study aimed at evaluating the incidence and prognostic relevance of an increased total to ionized calcium ratio (T/I Ca2+ ratio) and its association to hepatic dysfunction. Methods: We performed a prospective observational study on n = 208 critically ill patients with acute kidney injury (AKI) and necessity for CRRT with regional citrate anticoagulation (CRRT-citrate) between September 2009 and September 2011. Critical illness was estimated by Simplified Acute Physiology Score II; hepatic function was measured with indocyanine green plasma disappearance rate. After achieving a steady state of calcium homeostasis patients were classified into tertiles according to the T/I Ca2+ ratio (2+ ratio was determined as an independent predictor for 28-day mortality in critically ill patients with AKI on CRRT-citrate confirmed by receiver operating characteristics and multivariate analysis (Area under the curve 0.94 ± 0.02; p2+ ratio ≥2.4 independently predicted a 33.5-fold (p2+ ratio and the hepatic clearance (p2+ ratio is closely related to the clinical outcome and emerged as an independent predictor of 28-day mortality. Larger studies are required to define the cut-off and predictive value for the T/I Ca2+ ratio. This ratio is associated with hepatic and/or multi-organ dysfunction and therefore an important therapeutic target.
- 29 May 2012
- Published by Springer Nature in Critical Care
- Vol. 16 (3) , R97
Open AccessTotal-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
Introduction: Regional citrate anticoagulation is safe, feasible and increasingly used in critically ill patients on continuous renal replacement therapy (CRRT). However, in patients with hepatic or multi-organ dysfunction, citrate accumulation may lead to an imbalance of calcium homeostasis. The study aimed at evaluating the incidence and prognostic relevance of an increased total to ionized calcium ratio (T/I Ca2+ ratio) and its association to hepatic dysfunction. Methods: We performed a prospective observational study on n = 208 critically ill patients with acute kidney injury (AKI) and necessity for CRRT with regional citrate anticoagulation (CRRT-citrate) between September 2009 and September 2011. Critical illness was estimated by Simplified Acute Physiology Score II; hepatic function was measured with indocyanine green plasma disappearance rate. After achieving a steady state of calcium homeostasis patients were classified into tertiles according to the T/I Ca2+ ratio (2+ ratio was determined as an independent predictor for 28-day mortality in critically ill patients with AKI on CRRT-citrate confirmed by receiver operating characteristics and multivariate analysis (Area under the curve 0.94 ± 0.02; p2+ ratio ≥2.4 independently predicted a 33.5-fold (p2+ ratio and the hepatic clearance (p2+ ratio is closely related to the clinical outcome and emerged as an independent predictor of 28-day mortality. Larger studies are required to define the cut-off and predictive value for the T/I Ca2+ ratio. This ratio is associated with hepatic and/or multi-organ dysfunction and therefore an important therapeutic target.